A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (BRAVE I)
The reason for this study is to see how effective and safe the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE).
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 809 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Actual Study Start Date: August 2, 2018
Estimated Primary Completion Date: October 30, 2021
Estimated Study Completion Date: November 30, 2021
Arms:
- Experimental: Baricitinib High Dose
- Experimental: Baricitinib Low Dose
- Placebo Comparator: Placebo
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 809 |
| Actual Study start date | 02 August 2018 |
| Estimated Study Completion Date | 30 November 2021 |